.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,271,968

« Back to Dashboard

Claims for Patent: 9,271,968

Title:Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin .delta. and rifaximin .epsilon. useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Inventor(s): Viscomi; Giuseppe Claudio (Sasso Marconi, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Calderara di Reno, IT), Barbanti; Maria (Bologna, IT), Braga; Dario (Bologna, IT)
Assignee: ALFA WASSERMANN S.P.A. (IT)
Application Number:14/262,612
Patent Claims: 1. A pharmaceutical composition comprising a therapeutically effective amount of rifaximin together with excipients, wherein the rifaximin has a X-ray powder diffraction pattern peaks at about 5.7.degree..+-.0.2, 6.7.degree..+-.0.2 and 8.0.degree..+-.0.2.

2. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises a peak at about 7.1.degree..+-.0.2, 2.theta..

3. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at about 10.4.degree..+-.0.2, 2.theta..

4. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at about 11.3.degree..+-.0.2, 2.theta..

5. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at about 7.1.degree..+-.0.2 and 10.8.degree..+-.0.2, 2.theta..

6. The pharmaceutical composition of claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at about 12.1.+-.0.2, 2.theta..

7. The pharmaceutical composition according to claim 1 wherein the X-ray powder diffractogram further comprises peaks at 7.1.degree..+-.0.2, 8.7.degree..+-.0.2, and 10.4.degree..+-.0.2, 2.theta..

8. The pharmaceutical composition of claim 1, wherein the rifaximin has an X-ray powder diffraction pattern peaks at about 5.7.degree..+-.0.2, 6.7.degree..+-.0.2, 7.1.degree..+-.0.2, 8.0.degree..+-.0.2, 8.7.degree..+-.0.2, 10.4.degree..+-.0.2, 11.3.degree..+-.0.2, 12.1.degree..+-.0.2, 17.0.degree..+-.0.2, 17.3.degree..+-.0.2, 17.5.degree..+-.0.2, 18.5.degree..+-.0.2, 18.8.degree..+-.0.2, 19.1.degree..+-.0.2, 21.0.degree..+-.0.2 and 21.5.degree..+-.0.2, 2.theta..

9. The pharmaceutical composition of claim 1, wherein the composition has a water content of between 2.5% and 6.0%.

10. The pharmaceutical composition according to claim 1 wherein the excipients are selected from the group consisting of diluting agents, binding agents, lubricating agents, disintegrating agents, coloring agents and flavoring agents.

11. The pharmaceutical composition according to claim 1, wherein the composition is in a solid form selected from granules, tablets capsules, and powders in sealed packets.

12. A pharmaceutical composition comprising a therapeutically effective amount of rifaximin together with excipients wherein the rifaximin has X-ray powder diffraction pattern peaks at about 7.3.degree..+-.0.2, 8.2.degree..+-.0.2 and 10.3.degree..+-.0.2, 2.theta..

13. The pharmaceutical composition of claim 12, wherein the X-ray powder diffraction pattern further comprises peaks at 7.0.degree..+-.0.2 and 11.1 .degree..+-.0.2, 2.theta..

14. The pharmaceutical composition of claim 12, wherein the X-ray powder diffraction pattern further comprises peaks at about 12.4.degree..+-.0.2, 8.7.degree..+-.0.2 and 11.7.degree..+-.0.2,2.theta..

15. The pharmaceutical composition of claim 11, wherein the X-ray powder diffraction pattern further comprises peaks at about 17.5 .degree..+-.0.2 and 21.5.degree..+-.0.2, 2.theta..

16. The pharmaceutical composition according to claim 11 wherein the X-ray powder diffraction pattern peaks comprises peaks at about 5.7.degree..+-.0.2, 6.7.degree..+-.0.2, 7.1.degree..+-.0.2, 8.0.degree..+-.0.2, 8.7.degree..+-.0.2, 10.4.degree..+-.0.2, 11.3.degree..+-.0.2, 12.1.degree..+-.0.2, 17.0.degree..+-.0.2, 17.3.degree..+-.0.2, 17.5.degree..+-.0.2, 18.5.degree..+-.0.2, 18.8.degree..+-.0.2, 19.1.degree..+-.0.2, 21.0.degree..+-.0.2 and 21.5.degree..+-.0.2, 2.theta..

17. The pharmaceutical composition according to claim 12, wherein the excipients are selected from the group consisting of diluting agents, binding agents, lubricating agents, disintegrating agents, coloring agents and flavoring agents.

18. The pharmaceutical composition according to claim 12, wherein the composition is in a solid form, selected from granules, tablets capsules, and powders in sealed packets.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc